Related Experiment Videos
Current concepts in cyclooxygenase inhibition in breast cancer
1Breast Surgery Unit, Level 3 St James' Wing, St George's Hospital Medical School, London SW17 OQT, UK. gsinghranger@yahoo.co.uk
Abstract:
The prospect that simple medications such as non-steroidal anti-inflammatory drugs (NSAIDs) could be recruited into the physician's armamentarium of anticancer drugs is intriguing, especially in the context of breast cancer, one of the leading causes of mortality in the Western world. There has consequently been a wider exploration of the role of cyclooxygenase (COX) in breast cancer, and we now accept that COX-2, one of its isoenzymes, is clearly implicated in the pathogenesis of the disease. This would seem to translate into a viable role for cyclooxygenase inhibitors in the treatment and prevention of breast cancer, but also raises issues regarding safety and tolerability of these drugs. In this article we discuss the theoretical consequences of cyclooxygenase inhibition, the significance of findings from experimental studies, large scale epidermiological investigations, and the relevance of large population studies of COX-2 inhibitors such as CLASS and VIGOR.
Insights
Non-steroidal anti-inflammatory drugs (NSAIDs), particularly targeting cyclooxygenase-2 (COX-2), show potential in breast cancer treatment and prevention. However, their safety and tolerability require careful consideration.
Area of Science:
- Oncology
- Pharmacology
Background:
- Breast cancer is a leading cause of mortality globally.
- Cyclooxygenase-2 (COX-2) is implicated in breast cancer pathogenesis.
- NSAIDs are being explored for their anticancer potential.
Purpose of the Study:
- To explore the role of cyclooxygenase (COX) in breast cancer.
- To evaluate the potential of COX inhibitors in breast cancer treatment and prevention.
- To discuss the safety and tolerability of COX inhibitors.
Main Methods:
- Review of theoretical consequences of COX inhibition.
- Analysis of experimental studies.
- Examination of epidemiological and large population studies (e.g., CLASS, VIGOR).
Main Results:
- COX-2 is clearly implicated in breast cancer development.
- COX inhibitors show promise for breast cancer therapy and prevention.
- Safety and tolerability are key concerns for COX inhibitor use.
Conclusions:
- COX inhibition presents a viable strategy for breast cancer management.
- Further research is needed to balance efficacy with safety.
- Understanding COX pathways is crucial for novel breast cancer treatments.